Ratings by Guggenheim (Whitney Ljem)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/16/2026 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 1/5/2026 | Amicus Therapeutics | FOLD | Downgrade | Neutral (Buy) |
14.27 (14.49) |
1.54% | Details | |
| 11/3/2025 | Incyte | INCY | Upgrade | Buy (Neutral) |
93.48 (97.98) |
4.81% | Details | |
| 3/18/2025 | Incyte | INCY | Downgrade | Neutral (Buy) |
62.01 (97.98) |
58.01% | Details | |
| 5/14/2024 | Amicus Therapeutics | FOLD | Upgrade | Buy (Neutral) |
9.04 (14.49) |
60.29% | Details | |
| 12/4/2023 | Incyte | INCY | Upgrade | Buy (Neutral) |
54.02 (97.98) |
81.38% | Details | |
| 8/3/2022 | Incyte | INCY | Downgrade | Neutral (Buy) |
72.58 (97.98) |
35% | Details | |
| 6/11/2021 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/22/2021 | Alnylam Pharmaceuticals | ALNY | Downgrade | Neutral (Buy) |
155.06 (292.58) |
88.69% | Details | |
| 1/4/2021 | Incyte | INCY | Upgrade | Buy (Neutral) |
86.98 (97.98) |
12.65% | Details | |
| 1/4/2021 | Gilead Sciences | GILD | Upgrade | Buy (Neutral) |
58.26 (128.99) |
121.4% | Details | |
| 1/31/2020 | Vertex | VRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 1/21/2020 | Gilead Sciences | GILD | Downgrade | Neutral (Buy) |
62.98 (128.99) |
104.81% | Details | |
| 11/25/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 11/19/2019 | Vertex | VRTX | Upgrade | Buy (Neutral) |
210.00 (428.34) |
103.97% | Details | |
| 10/25/2019 | Gilead Sciences | GILD | Maintain | Buy (N/A) |
|
Details | ||
| 9/17/2019 | Orchard Therapeutics | ORTX | New Coverage | Buy (N/A) |
15.50 (16.70) |
7.74% | Details | |
| 7/30/2019 | uniQure BV | QURE | Downgrade | Neutral (Buy) |
65.56 (29.88) |
-54.42% | Details | |
| 2/28/2019 | uniQure BV | QURE | Maintain | Buy (N/A) |
|
Details | ||
| 12/18/2018 | Vertex | VRTX | New Coverage | Neutral (N/A) |
170.06 (210.00) |
23.49% | Details | |
| 12/18/2018 | uniQure BV | QURE | New Coverage | Buy (N/A) |
28.14 (65.56) |
132.98% | Details | |
| 12/18/2018 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Neutral (N/A) |
93.11 (54.66) |
-41.3% | Details | |
| 12/18/2018 | Amicus Therapeutics | FOLD | New Coverage | Buy (N/A) |
10.51 (14.49) |
37.87% | Details | |
| 12/18/2018 | Alnylam Pharmaceuticals | ALNY | New Coverage | Buy (N/A) |
77.13 (292.58) |
279.33% | Details | |
| 12/17/2018 | Gilead Sciences | GILD | New Coverage | Buy (N/A) |
65.57 (62.98) |
-3.95% | Details |
